Chronic Lymphocytic Leukemia

Tadeusz Robak, MD, PhD, discusses subsequent treatment after discontinuation of ibrutinib on the phase 3 RESONATE-2 trial in patients with chronic lymphocytic leukemia.

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation. 

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, close out the program answering audience questions regarding potential adverse events surrounding the utilization of BTK inhibitors in the management of chronic lymphocytic leukemia.

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review strategies for managing hypertension in patients with CLL.

Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.

The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.

The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Meghan Thompson, MD, discusses the safety profile of pirtobrutinib in patients with Richter transformation.

Chan Cheah, MBBS, discusses the toxicity profile of TG-1701 with and without ublituximab and umbralisib in patients with chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the unique pharmacodynamic profile of lisaftoclax, the similar responses seen across cohorts, and the favorable tolerability of the drug.

An upgraded model of the clonoSEQ® B-cell Clonality diagnostic tool has been released, which will now include IGHV mutation status for patients with chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Harry Paul Erba, MD, PhD, discusses selecting between ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

The FDA has granted an orphan drug designation to LAVA-051, a CD1d-targeted Gammabody, for the treatment of patients with chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

Farrukh Awan shares a case of a patient with a cardiac history recently diagnosed with CLL requiring treatment.

Two experts discuss strategies for managing atrial fibrillation in patients with CLL on BTKi therapy.

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.